Posted by Michael Wonder on 19 Jul 2021
Foundation Medicine expands indication for FoundationOne Liquid CDx to be used as a companion diagnostic for Tabrecta (capmatinib)
15 July 2021 - Tabrecta is the first FDA approved MET inhibitor for patients with metastatic non-small cell lung cancer with MET exon 14 skipping.
Foundation Medicine today announced that it has received approval from the U.S. FDA for FoundationOne Liquid CDx to be used as a companion diagnostic to aid in identifying patients with MET exon 14 skipping in metastatic non-small cell lung cancer for whom treatment with Tabrecta (capmatinib) may be appropriate.
